Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance

Abstract

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediated activation; however, the outcomes in patients are not so promising. Increasing evidence show that MET has kinase-independent effects on tumorigenesis and dissemination, which explains the low efficacy in kinase inhibition-based strategy. VHH is the recombinant variable region of Camelid heavy-chain antibody. As a nanoscale antigen-binding unit, VHH has become an appealing drug candidate in cancer therapy. In our study, we choose a novel strategy to construct an anti-MET VHH pool against the whole ecto-domain of MET. Comparing to monoclonal antibody or single VHH, the anti-MET VHH pool strongly promotes MET degradation through Clathrin-dependent endo-lysosomal pathway. Thus, the anti-MET VHH pool not only blocks kinase activity of MET, but also reduces protein level of MET. As a consequence, anti-MET VHH pool dramatically suppresses cancer cell proliferation, viability, and colony formation in vitro, and inhibits tumorigenesis and growth in mice. Taken together, VHH pool-based strategy greatly improves MET-targeted therapeutic effects on cancer.

USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

“…According to previously established protocols (16), to analyze cellular proliferation, 1 Â 10 4 of the indicated cells were seeded in six-well tissue culture plates at day 0 (in triplicate) in 3 mL of normal growth medium. The medium was changed every day.…”

The AKT-independent MET–V-ATPase–MTOR axis suppresses liver cancer vaccination

“…Various reports have suggested that MET affects tumor progression and survival under therapeutic stress through a complicated process, which partially explains the previous failures of drugs targeted to HGF-MET-signaling. [10][11][12][13][36][37][38][39][40] Although MET is involved in neutrophil-mediated cancer immunity, contradictory conclusions regarding the pro-or anticancer effects of MET on neutrophils have largely limited its further exploitation and application in cancer immunotherapy. 41,42 Moreover, Li et al found that MET inhibitors stabilize PD-L1 to cause liver cancer cells to escape the body's immune surveillance; 11 in contrast, Martin et al observed that MET inhibition reverses interferon γ-induced upregulation of PD-L1 expression levels in MET-amplified cancers.…”

Antibody variable region engineering for improving cancer immunotherapy

“…Although it has been argued that cMET may not be the best biomarker for enrolling patients, cMET and HGF may have kinase‐independent pathways in tumorigenesis that render the kinase region targeted by anti‐HGF/cMET mAbs and anti‐HGF nanobodies obsolete [ 73 ]. To address this issue, nanobodies against the whole cMET ectodomain were developed and demonstrated higher uptake by tumor tissues compared to that by normal tissues and delayed tumor growth compared with saline control [ 19 , 74 ].…”